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Key Message 
Immune checkpoint inhibitors as monotherapy and in combination are effective treatments in 
melanoma.  Immune-related side effects may emerge, including neurological toxicity.  This rare side 
effect may be unpredictable and result in major morbidity, but patients may survive for years.  We 
review our experience as well as the literature and provide an approach to management. 
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical 
Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 
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Abstract 
Background 
Treatment with immune checkpoint inhibitors (ICPi) has greatly improved survival for patients with 
advanced melanoma in recent years. Anti-CTLA-4 and anti-PD1 antibodies have been approved 
following large Phase III trials. Immune-related neurological toxicity of varying severity has been 
reported in the literature. The cumulative incidence of neurotoxicity amongst ipilimumab, nivolumab 
and pembrolizumab is reported as <1% in published clinical trials. We aimed to identify the incidence 
of neurotoxicity in our institution across anti-CTLA4 and anti-PD-1 antibodies, including the 
combination of ipilimumab with nivolumab.  We also review the existing literature and propose an 
investigation and management algorithm. 
 
Methods 
All patients with advanced melanoma treated with ipilimumab, nivolumab, pembrolizumab or the 
combination of ipilimumab and nivolumab (ipi+nivo), managed at the Royal Marsden Hospital 
between September 2010 and December 2015, including patients on (published) clinical trials were 
included.  Medical records for each patient were reviewed and information on neurotoxicity recorded. 
A systematic search strategy was performed to collate existing reports of neurological toxicity. 
 
Results 
In total, 413 immunotherapy treatment episodes in 352 patients were included, with median follow-up 
of 26.7 months. Ten cases of neurotoxicity were recorded, affecting 2.8% of patients overall, ranging 
from grade 1 to 4, affecting both central and peripheral nervous systems.  A rate of 14% was noted 
with ipi+nivo. Three of five patients commenced on corticosteroids responded to these. Six patients 
had made a full recovery at the time of reporting. A favorable radiological response was found in 
seven of the ten cases. Unusual presentations are described in detail. 
 
Conclusions 
Neurological toxicity is not uncommon, and may be more frequent in patients treated with combination 
ipi+nivo. Patterns of presentation and response to treatment are varied. A prompt and considered 
approach is required to optimize outcomes in this group of patients. 
 
Keywords 
Immune-related adverse event, neurological toxicity, melanoma, anti-CTLA-4, anti-PD-1 
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Introduction 
Recent therapeutic advances have substantially improved the prognosis of advanced melanoma. 
Ipilimumab, nivolumab and pembrolizumab, monoclonal antibodies directed against immune 
checkpoints, are all approved for treatment and have substantially improved survival outcomes over 
cytotoxic therapies [1–4]. Nivolumab may be combined with ipilimumab, resulting in the highest 
response rate and longest progression free survival (PFS) compared to monotherapy with either 
agent [5]. Ipilimumab also improves recurrence-free survival when used in the adjuvant setting [6]. 
 
Toxicity from ICPi occurs due to both upregulation of the immune system and interference with self-
tolerance. Rates of moderate and severe immune-related adverse events (irAEs) range from 10-15% 
for nivolumab and pembrolizumab, 20-30% for ipilimumab and 55% for the combination of ipilimumab 
and nivolumab (ipi+nivo) [5,7]. Frequently occurring irAEs include dermatitis, colitis, hepatitis, thyroid 
dysfunction and hypophysitis. Reassuringly the vast majority of toxicity is reversible with 
corticosteroids and other immune-modulating medication (IMM). 
 
Neurological irAEs are rare, occurring in <1% patients treated in large clinical trials [1-3,5-7]. To date 
there is limited data available on the incidence of neurotoxicity outside reported clinical trials and most 
descriptions are contained within anecdotal case reports (see Table S1). Neurological toxicity was not 
reported in the Checkmate-067 trial [5] and no cases in the literature have been attributed to ipi+nivo 
yet.  The best approach to its management is not defined. 
 
We aimed to review our population of ICPi treated patients with advanced melanoma and identify the 
frequency of neurological irAEs across all ICPi therapies. We provide vignettes of complex case 
presentations and their treatment, as well as a proposed algorithm for management, in addition to a 
review of the available literature. 
 
Methods 
We identified all patients with advanced melanoma treated with ipilimumab, nivolumab, 
pembrolizumab, or ipi+nivo, managed at the Royal Marsden Hospital between September 2010 and 
December 2015.  This included patients on published clinical trials.  The medical records for each 
patient were reviewed and neurological symptoms attributed to ICPi therapy were noted. Where 
patients had brain or leptomeningeal metastases and a neurological change or decline consistent with 
this on treatment, we did not record such episodes as drug-related neurological toxicity. Severity was 
graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 
Information on symptoms, pre-existing neurological or autoimmune conditions, investigations, 
treatment, need for admission and resolution of symptoms was collected.  Descriptive statistics were 
used to analyse the data whilst the Kaplan-Meier method was used to summarise the overall survival 
estimates from initiation of treatment to death of any cause. Response to treatment by RECIST 
version 1.1 was documented in those affected by neurotoxicity.  Time to RECIST progression and 
time to treatment failure (defined as time to next line of therapy or death) were also calculated for the 
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patients with neurotoxicity. A systematic search strategy was performed on Pubmed using the terms 
"ipilimumab", "nivolumab" or "pembrolizumab" and "neurological", "neuropathy", "neurotoxicity", 
“nervous”, “neuritis”, “meningitis”, “encephalitis”, “encephalopathy” to identify published cases and 
case series. 
 
Results 
There were 352 patients with melanoma who were treated with one or more ICPi from September 
2010 until December 2015.  In total, there were 413 treatment episodes (ie 61 patients received more 
than one ICPi). The majority were male (197; 56%) and the median age of the total population was 59 
years. Median follow-up in our cohort was 26.7 months (IQR: 13.9 – 37.9 months).Ten episodes of 
immune-related neurological toxicity were recorded (10/413 treatment episodes, 2.4%; 10/352 
patients, 2.8%), ranging from grade 1 to grade 4, and none recurring in the same patient.  Three of 
the 10 cases were attributed to ipi+nivo. Ten patients treated on the Checkmate-067 trial [5] remain 
blinded to therapy. See Table 1 for frequency by type of ICPi and grade. 
 
Table 1 Frequency and severity of immune-related toxicity by immune checkpoint therapy 
 
Of these ten cases, median age was 67 years (range 51-83), 4 were male.  Four of 10 occurred 
during first-line treatment. Predominantly peripheral nervous system disorders were identified (7/10), 
of which four were grade 3 or 4. Two of the 10 patients required a prolonged inpatient admission 
>3months.  Corticosteroid therapy was initiated in 5 of the 10 cases, and 3 cases were steroid-
responsive. Seven patients made a full recovery, the time to which ranged from 7 to 29 weeks 
(median 9.4 weeks). Three patients did not have complete resolution of toxicity at the time of this 
review. Table 2 summarises the clinical details of these 10 cases, the investigations performed and 
treatment. 
 
In 7 of the 10 patients with neurotoxicity an objective response was noted: 5 with partial response 
(PR) and 2 with complete response (CR). Six of the10 patients had progressed at the time of this 
review. The median duration of response was 13.1 months (range 1.0-25.9).  Five patients 
commenced another drug treatment with a median time to treatment failure of 2.9 months (range 1.7-
41.0). Several patients meeting criteria for RECIST PD did not require another line of treatment for 
several months. The median overall survival of patients experiencing neurotoxicity was greater than in 
the patients who did not develop neurotoxicity: 45.7 months (IQR 45.7m – 45.7m) versus 11.2 months 
(IQR 4.8m – 36.6m), albeit there were only 10 neurotoxicity cases with 2 deaths amongst them. There 
was no clear association with conditions such as diabetes mellitus, stroke, hypothyroidism, or 
previous ICPi therapy, though the prevalence of these factors was low in this group of cases. 
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Table 2 Summary of cases of immune-related neurotoxicity at our Institution 
 
Case 1 vignette 
A 78-year-old male commenced ipilimumab (3mg/kg) as first-line treatment.  One week following the 
fourth infusion, he presented with subacute right leg weakness developing over one week and 
impaired sensation of the plantar surface of his feet. Neurological examination revealed moderate 
weakness in extension and flexion of the hips and knees, dysaesthesia of hands and feet and 
areflexia of the triceps, knees and ankles. Examination of the CSF revealed raised protein at 0.74g/L, 
no lymphocytes, normal glucose. MRI of the brain and spine were unremarkable.  The patient was 
admitted for IV steroids with a provisional diagnosis of ipilimumab-related lumbosacral plexopathy.  
Following 24 hours of twice daily 8mg IV dexamethasone, he deteriorated. 
 
The patient was converted to 2mg/kg IV methylprednisolone and transferred to a tertiary neurology 
centre. A diagnosis of acute sensorimotor polyradiculoneuropathy (a Guillain-Barre-like syndrome) 
was made.  Motor nerve conduction studies demonstrated proximal demyelinating features but 
sensory studies were normal.  Electromyography demonstrated a mildly reduced interference pattern 
only.  Plasmapheresis was conducted on day five following his presentation due to a lack of clinical 
improvement with intravenous steroids (discontinued at this point due to plateau in neurological 
status). However, dysarthria and dysphagia developed within a week of completing plasmapheresis 
and nasogastric feeding was commenced.  At his nadir, 4 weeks after onset, he was paraplegic and 
had limited use of his arms.  Methylprednisolone 1mg/kg was reinstituted and weaned over 2 months. 
The neuropathy stabilised over the 5
th
 week after symptom onset.  
 
This patient’s clinical course was characterised by repeat episodes of pneumonia necessitating 
ventilation and then a weaning tracheostomy. Re-imaging showed a PR. After 3 months, he regained 
some power in his legs. Five months from onset the patient’s steroids (weaned down to 5mg oral 
prednisolone 3 months from presentation) were ceased and he was discharged to a 
neurorehabilitation facility and demonstrates slow, ongoing improvement. 
 
Case 2 vignette 
A 79-year-old woman with a past medical history of Graves' disease commenced second-line 
nivolumab (3mg/kg).  She had been treated with ipilimumab 5 months prior and developed grade 3 
colitis after cycle 1 requiring 3 months of glucocorticoid therapy and cessation of treatment. One week 
following cycle 4 nivolumab she presented with malaise and exertional dyspnoea. A comprehensive 
cardio-respiratory work-up was normal. One week after cycle 5 was due she re-presented with 
worsening dyspnoea and type 1 respiratory failure. Concurrent dysphagia was managed with 
nasogastric feeding. Pulmonary function testing revealed paradoxical abdominal motion in addition to 
low nasal sniff pressures (13cmH20), attributed to inspiratory muscle weakness.  IV 
methylprednisolone was commenced at 1.5mg/kg daily and in the absence of improvement she was 
moved to a critical care unit for non-invasive ventilation (NIV) 5 days later.  
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 Neurological examination revealed fatiguable muscle weakness in the limbs with bulbar dysfunction. 
Given the similarities with a myasthenic syndrome and lack of improvement with 5 days of 
methylprednisolone, empirical pyridostigmine was initiated. However a Tensilon test, acetylcholine 
receptor and neurological paraneoplastic antibodies were negative, as were electromyography and 
nerve conduction studies (including repetitive nerve stimulation). The working diagnosis was that of 
nivolumab-induced immune-related phrenic neuropathy resulting in diaphragmatic weakness and a 
bulbar palsy. After 2 weeks, IV immunoglobulin (IVIg) was commenced due to a plateau in symptoms 
and the patient clinically improved over the next couple of weeks. IV steroid was switched to oral and 
the patient was transferred to a specialised respiratory neurorehabilitation centre a month later. She 
was discharged home, off all corticosteroids, 4 months following initial presentation, and full resolution 
of symptoms occurred 1 month later.  Surveillance imaging demonstrates no new measurable disease 
at 54 months post-treatment initiation. 
 
Case 3 vignette 
A 67-year-old male was commenced on combination ipilimumab (3 mg/kg) and nivolumab (1mg/kg).  
Two weeks into cycle 1 he was admitted to hospital with new lower back pain associated with 
paraesthesia of his thighs, constipation, a grade 3 ALT derangement and progressive rash. On 
examination the lower limbs had reduced power in hip flexion, absent knee but brisk ankle reflexes, 
and normal plantar responses.  Symmetrical loss of fine touch and pain was demonstrated in the T10-
L2 dermatomes bilaterally.  The patient was commenced on 2mg/kg IV methylprednisolone. 
 
After 48 hours, the left-sided thoracic sensory deficits progressed. Specialist neurology input was 
sought and a diagnosis of autoimmune bilateral lumbar plexopathy was made, though this did not 
account for the thoracic-level paraesthesia for which possible transverse myelitis was considered. 
MRI of the brain and spine were normal however.  CSF analysis revealed elevated protein 1.26g/L, 
lymphocytes and mononuclear cells were noted (white blood cell count: <1 cu. mm.). Matching 
oligoclonal bands (IgG) were found in the paired serum and CSF samples.  Nerve conduction studies 
were normal. Autoimmune, vasculitis and blood-borne virus screens were normal.  On the fifth day 
there was a substantial improvement in the patient’s mobility and sensory deficits, in addition to 
reduction in the ALT to grade 2, and methylprednisolone was converted to oral prednisolone.   
 
Following intense input from physiotherapy and occupational therapy he was fit for discharge on a 
reducing dose of prednisolone. At 2 months his neurological symptoms had resolved. Prednisolone 
was weaned, however the patient has required ongoing low-dose steroids to manage fevers 
complicating his next-line BRAF-targeted therapy. Surveillance imaging one month following 
treatment demonstrated an excellent PR to combination immunotherapy. Imaging at two months 
however indicated disease progression. 
 
Discussion 
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Although ICPi have revolutionised the treatment of melanoma, they have given rise to a novel set of 
adverse effects that require early recognition, appropriate investigation and prompt, careful 
management. This is the first systematically reported, single-institution series of neurotoxicity across 
all ICPi treatments in melanoma, including the combination of ipilimumab with nivolumab. We report 
an overall immune-related neurotoxicity rate of 2.4%, over twice that reported in large phase III clinical 
trials [1-3, 5-7]. In particular, 14% of patients treated with combination ipilimumab and nivolumab 
developed a neurological irAE and all of these cases had another concurrent irAE. Despite a median 
time to symptom resolution of 9.4 weeks in our cohort (noting that some did not resolve), the median 
survival for this group is very long (45.7 months, CI 13.8-NE) and 70% of patients with neurotoxicity 
experienced an objective response, durable in 40%.  This justifies intensive care and support in the 
acute treatment and rehabilitation of neurotoxicity in this group of patients. 
 
Two series report immune-related neurotoxicity in 1.5% (11/752) of ipilimumab-treated patients [8] 
and 3.2% (16/496) of anti-PD-1 treated patients [9], rates similar to our cohort (1% and 3% 
respectively). Dysgeusia was included in these series (2/11 ipilimumab cases and 1/16 anti-PD-1). 
We have also summarised the published cases of neurological sequelae secondary to ICPi in 
Supplementary Table 1. Peripheral neuropathy, Guillain-Barre-like syndromes, cranial nerve palsies, 
demyelination and myasthenia gravis-type syndromes are all recognised adverse effects [10–12]. 
There is a bias in the literature towards reporting of neurotoxicity with ipilimumab, likely reflecting its 
earlier availability. Overall the incidence of irAEs associated with ipilimumab is greater in comparison 
with anti-PD-1 monotherapy [5, 7]. However, in our series and that of Zimmer et al [9], this does not 
seem to be the case for neurological toxicity. As anti-PD-1 treatment is continued for a longer 
duration, there is arguably a greater chance of developing neurological sequelae at a late stage. 
 
Our report presents several cases of neurological toxicity that do not neatly fit the characteristics of 
‘typical’ neurological syndromes, such as in case vignette 3 where the lumbar plexopathy could not 
account for subjective thoracic sensory changes, and the bilateral phrenic nerve palsy in case 
vignette 2 associated with bulbar dysfunction. Both peripheral and central nervous systems may be 
affected and there does not appear to be a clear predominance of one over the other, although in our 
cohort the peripheral nervous system was more commonly impacted (70% versus 30% cases). 
 
There is a risk of neurological irAEs at any stage throughout the course of treatment with immune-
checkpoint agents, however presentations within the first 4 months predominated in our cohort (8/10, 
80%). The existing series of ipilimumab and anti-PD-1 neurotoxicity also confirm the predominance of 
early presentations with only 27% (3/11) patients in the ipilimumab series [8] developing neurological 
toxicity after 4 months and 25% (4/16) in the anti-PD-1 series [9].  
 
Generally the majority of irAEs can be effectively reversed with corticosteroids and, in keeping with 
this, it appears that most neurological toxicity is also steroid-responsive (3 of 5 steroid-treated cases 
in our cohort). However, not all of our patients with neurotoxicity had a clear response to steroids (eg 
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case vignettes 1 and 2) and alternative treatments such as IVIg and plasmapheresis may need to be 
employed in situations with an antibody-mediated pathogenesis. The area of greatest contention with 
the use of steroids is in Guillain-Barre-like syndromes where corticosteroids in cases of idiopathic 
onset are not beneficial (but have not been shown to be harmful), but plasma exchange or IVIg 
initiated within 2 weeks of onset can improve recovery time [13, 14]. It is important to note that allied 
health practitioners played significant roles in the recovery of neurotoxicity patients managed at our 
institution. We propose a comprehensive investigation and treatment algorithm (Figure 1A, 1B and 
1C) to aid clinicians in managing cases of immune-related toxicity. 
 
Not all patients experience complete resolution of neurotoxicity. Three patients (30%) in our cohort 
had ongoing symptoms at the time of review.  In the ipilimumab series by Voskens et al [8], 5/11 
(45%) cases resolved, whereas only 6/16 (38%) cases resolved in the anti-PD-1 treated series by 
Zimmer et al [9]. The individual duration of follow-up was not clear in these reports and given patients’ 
recovery can take months, such figures may under-represent resolution rates.  Looking at case 
reports is not reliable for such information as there is likely to be a bias towards positive outcomes. 
Like the immune-related endocrinopathies, neurotoxicity has the potential to cause permanent 
damage and disability.  It should be specifically addressed in informed consent, especially in patients 
receiving combination ipi+nivo where rates are potentially higher, and in patients receiving adjuvant 
ICPi therapy.  This is particularly important as several patients in our series experienced durable 
responses and have lived for years.   
 
Although the small numbers preclude any definitive statements, neurotoxicity may be a predictor of 
response.  In our cohort 70% had an objective response by RECIST criteria and many were durable.  
The objective response rate in the other reported series approximated that of the agents used: 2/11 
treated with ipilimumab had a PR [8] and 8/16 had an objective response in the anti-PD-1 treated 
series [9]. 
 
Whilst there is very little data on the specific pathogenesis of immune checkpoint-related neurological 
toxicity, inflammation around endoneurial microvessels and sub-perineural oedema and inflammation 
may explain some presentations [15]. PD-1 is also expressed on B cells and blockade has been 
shown to enhance activation and proliferation [16]. Inhibition of CTLA-4 expressed on certain T helper 
and T regulatory cells may augment B cell responses and fail to suppress antibody responses [17], 
thereby also predisposing to antibody-mediated disease.     
 
Limitations 
We acknowledge there are limitations within our retrospective review, mostly due to the small number 
of affected patients from which we cannot draw firm conclusions. Subtle (grade 1) changes may have 
been under-documented in the medical records. Our overall survival figures are calculated from the 
first immune checkpoint therapy and some patients may have had prior therapies such as BRAF 
inhibitors.  Unlike the other reports, we did not record dysgeusia as a neurological toxicity.  We made 
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the assumption that neurological change occurring in the context of progressive central nervous 
system disease was not a toxicity per se. Ten patients' treatments remain blinded to the authors and 
therefore their data cannot fully contribute to our conclusions at the time of writing. Nonetheless we 
feel our data contributes to the small body of literature on this important subject. 
 
Conclusion 
Immune-checkpoint inhibition is an established and effective treatment paradigm for patients with 
metastatic melanoma. As the use of these agents increases in other tumour types it is important for 
clinicians to be aware of serious potential adverse effects, such as immune-related neurological 
toxicities, which may have lasting consequences. Whilst these are rare and often responsive to 
steroid therapy, they can present in a number of patterns, often early in the course of treatment, and 
unfortunately resolution is not always seen.  Thorough neurological examination and access to 
specialist investigations in order to classify and successfully treat these conditions is important, as 
many patients have a reasonable chance of long-term disease control. It is clear that further research 
is required to study the patterns of neurotoxicity, identify the underlying pathogenesis and to optimise 
the treatment paradigm.  Development of an international database would be helpful to further refine 
management approaches in this complex area. 
 
 at Institute of Cancer Research on N
ovem
ber 20, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Disclosures: 
No funding has been received in relation to this manuscript.JL is a non-remunerated consultant for 
Novartis, Pfizer, BMS, MSD, Roche/Genentech, GSK and Eisai and receives institutional research 
support from Pfizer, BMS, Novartis and MSD.JL and MG are supported by the National Institute for 
Health Research Royal Marsden Hospital and Institute of Cancer Research Biomedical Research 
Centre (NIHR RMH/ICR BRC).  ST is a Cancer Research UK (CRUK) Clinician Scientist and is 
funded by CRUK (Grant Ref C50947/A18176) and the NIHR RMH/ICR BRC(Grant Ref A109). All 
remaining authors have declared no conflicts of interest. 
References 
1.  Robert C, Long G V, Brady B et al. Nivolumab in previously untreated melanoma without 
BRAF mutation. N. Engl. J. Med. 2015; 372(4):320–30. 
2.  Weber JS, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with 
advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a 
randomised, controlled, open-label, phase 3 trial. Lancet. Oncol. 2015; 16(4):375–84. 
3.  Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice 
chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, 
phase 2 trial. Lancet. Oncol. 2015; 16(8):908–18. 
4.  Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus Dacarbazine for Previously 
Untreated Metastatic Melanoma. N. Engl. J. Med. 2011; 364(26):2517–2526. 
5.  Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or 
Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015; 373(1):23–34. 
6.  Eggermont AMM, Chiarion-Sileni V, Grob J-J et al. Adjuvant ipilimumab versus placebo after 
complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-
blind, phase 3 trial. Lancet. Oncol. 2015; 16(5):522–30. 
7.  Robert C, Schachter J, Long G V et al. Pembrolizumab versus Ipilimumab in Advanced 
Melanoma. N. Engl. J. Med. 2015; 372(26):2521–32. 
8.  Voskens CJ, Goldinger SM, Loquai C et al. The price of tumor control: an analysis of rare side 
effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS 
One 2013; 8(1):e53745. 
9.  Zimmer L, Goldinger SM, Hofmann L et al. Neurological, respiratory, musculoskeletal, cardiac 
and ocular side-effects of anti-PD-1 therapy. Eur. J. Cancer 2016; 60:210–25. 
10.  Yervoy - Summary of Product Characteristics. 
[http://www.medicines.org.uk/emc/medicine/24779]. 
11.  Opdivo - Summary of Product Characteristics. 
[https://www.medicines.org.uk/emc/medicine/30476]. 
12.  Keytruda - Summary of Product Characteristics. 
[https://www.medicines.org.uk/emc/medicine/30602]. 
 at Institute of Cancer Research on N
ovem
ber 20, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
13.  Hughes RAC, Swan A V, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré 
syndrome. Cochrane database Syst. Rev. 2014; (9):CD002063. 
14.  Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré 
syndrome. Cochrane database Syst. Rev. 2012; (7):CD001798. 
15.  Manousakis G, Koch J, Sommerville RB et al. Multifocal radiculoneuropathy during ipilimumab 
treatment of melanoma. Muscle Nerve 2013; 48(3):440–4. 
16.  Thibult M-L, Mamessier E, Gertner-Dardenne J et al. PD-1 is a novel regulator of human B-cell 
activation. Int. Immunol. 2013; 25(2):129–37. 
17.  Sage PT, Paterson AM, Lovitch SB, Sharpe AH. The coinhibitory receptor CTLA-4 controls B 
cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. 
Immunity 2014; 41(6):1026–39. 
 
 
 
Figure Legend 
Figure 1A: Proposed algorithms for investigation and management of neurological toxicity due to 
immune checkpoint inhibitors, Slide 1 
Figure 1B: Proposed algorithms for investigation and management of neurological toxicity due to 
immune checkpoint inhibitors, Slide 2 
Figure 1C: Proposed algorithms for investigation and management of neurological toxicity due to 
immune checkpoint inhibitors, Slide 3 
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Table 1 Frequency and severity of immune-related toxicity by immune checkpoint therapy 
 
 Ipilimumab Nivolumab Pembrolizumab Ipi + Nivo Blinded* Total 
Number treated 282 27 73 21 10 413 
Number with 
neurotoxicity 
(%) 
3 (1) 2 (7) 1 (2) 3 (14) 1 (10) 10 (2.4) 
Grade 1 0 1 1 0 0 2 
Grade 2 0 0 0 2 0 2 
Grade 3 2 0 0 1 1 4 
Grade 4 1 1 0 0 0 2 
*treated within the CheckMate-067 trial 
Ipi + Nivo = combination ipilimumab and nivolumab 
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Table 2 Summary of cases of immune-related neurotoxicity at our Institution 
Case 
&ICPi 
Central vs 
peripheral 
nervous 
system 
Toxicity Maximal 
Grade 
Time of 
onset 
Simultaneous 
non-neuro irAE 
Presenting 
symptoms 
Neurological history & 
potential risk factors 
Investigations Treatment Time to resolution Best 
response 
(time to 
best 
response) 
Overall 
survival 
from 
initiation 
of ICPi 
1 
Blinded 
 
Peripheral Motor 
peripheral 
neuropathy 
 
3 Cycle 1 None Weakness of 
hands and feet 
and associated 
functional 
impairment 
Previous stroke MRI Brain; 
Nerve conduction 
studies (NCS; 
normal) 
ICPi discontinued. 
Oral methylprednisolone  
1.5mg/kg (improved) 
Significant improvement 
after 4 months;  
complete resolution 
PR (2.5 
months) 
Alive after 
28 months, 
with 
ongoing 
PR 
50
51
52
53
54
55
56
57
58
59
60
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2 
ipilimumab 
(vignette 
#1) 
Peripheral Sensorimotor 
neuropathy 
with bulbar 
palsy 
(consistent 
with a 
Guillain-
Barre-like 
syndrome) 
 
4 Cycle 4 Haematological 
(neutropenia) 
Subacute leg 
then arm 
weakness with 
dysesthesia of 
feet causing falls 
None Bloods, MRI brain 
and whole spine, 
bronchoscopy, 
lumbar puncture, 
EMG & NCS 
(see details in 
vignette) 
 
ICPi discontinued. 
IV methylprednisolone 
2mg/kg (no immediate 
effect), plasmapheresis 
(initially stabilised), at 
nadir 
methylprednisolone 
1mg/kg re-started, 
required non-invasive 
ventilation, then 
tracheostomy 
Some improvement after 3 
months; ongoing inpatient 
neurorehabilitation for 
significant impairment 
 
PR (3.0 
months) 
Alive after 
8 months; 
ongoing 
PR 
3 
ipilimumab 
Central Aseptic 
meningitis 
 
3 Cycle 2 None Headache, 
drowsiness, 
nausea, 
vomiting 
Previous cisplatin, 
vincristine and 
dacarbazine; controlled 
hypothyroidism 
Bloods, lumbar 
puncture (a few 
lymphocytes 
seen), MRI brain 
ICPi discontinued. 
Admission for empirical 
intravenous cefuroxime, 
amoxicillin, aciclovir - no 
infection confirmed; no 
steroids commenced 
due to spontaneous 
improvement 
Complete resolution within 
10 days 
SD (4.3 
months) 
Died at 46 
months; 
PD at 6 
months 
4 
ipilimumab 
Central Aseptic 
meningitis 
 
3 Cycle 2 None Delirium Previous dacarbazine; 
previous stroke; 
controlled hypertension 
Bloods, lumbar 
puncture (normal), 
MRI brain 
ICPi discontinued. 
Admission for empirical 
antibiotics but no 
infective source 
confirmed. Oral 
prednisolone 
(improved); discharged 
after 2 weeks 
Complete resolution in 8 
weeks 
PD (2.8 
months) 
Died at 14 
months; 
PD at 3 
months 
5 
pembroliz
umab 
Peripheral Peripheral 
neuropathy 
 
1 Cycle 2 None Dysesthesiae None MRI whole spine ICPi treatment 
continued as planned 
Ongoing symptoms PD (1.5 
months) 
Alive after 
21 months; 
PD through 
treatment 
6 
nivolumab 
Peripheral Peripheral 
neuropathy 
 
1 Cycle 23 Skin Paraesthesiae Previous dacarbazine Bloods ICPi treatment 
continued as planned 
Complete resolution after 
21 weeks 
PR (2.1 
months) 
Alive after 
35 months; 
PD at 23 
months 
7 
nivolumab 
(vignette 
#2) 
Peripheral Phrenic nerve 
palsy with 
bulbar palsy 
 
4 Cycle 4 Hepatic Exertional 
dyspnoea 
Previous dacarbazine; 
past history Grave’s 
disease   
Bloods, 
MRI Brain, 
echocardiogram,  
bronchoscopy, 
ICPi discontinued. 
Admission for IV 
methylprednisolone 
1mg/kg (no 
Significant improvement 
after 4 months; complete 
resolution  
 
CR (7.1 
months) 
Alive after 
54 months; 
no PD 
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pulmonary function 
tests, Tensilon 
test, EMG & NCS 
(see details in 
vignette) 
 
improvement), 
pyridostigmine (patient 
stabilised), IVIg 
(improvement following 
further month in ITU), 
NIV 
8 
ipi+nivo 
(vignette 
#3) 
Peripheral Bilateral 
lumbar 
plexopathy 
 
3 Cycle 1 Hepatic, skin Lower back 
pain, proximal 
weakness and 
dysesthesiae of 
thighs 
None Bloods, lumbar 
puncture, MRI 
brain, MRI whole 
spine 
(see details in 
vignette) 
 
ICPi discontinued. 
Admission for 2mg/kg IV 
methylprednisolone 
(improved) 
Complete resolution after 
2months 
PR (1.6 
months) 
Alive after 
9 months; 
PD at 2 
months 
9 
ipi+nivo 
Peripheral Sensory 
(painful) 
peripheral 
neuropathy 
 
 
2 Cycle 7 Pituitary Paraesthesiae Previous carotid 
endarterectomy 
Bloods, MRI brain, 
NCS (normal) 
ICPi discontinued. 
Pregabablin (improved) 
Ongoing symptoms CR (2.6 
months) 
Alive after 
24 months; 
no PD 
10 
ipi+nivo 
Central Aseptic 
meningitis 
 
 
2 Cycle 1 Hepatic Headache and 
nausea 
Previous cavernoma Bloods, lumbar 
puncture (reactive 
lymphocytes, 
neutrophils and 
monocytes 
present), MRI brain 
Admission for 
observation only; no 
infection confirmed; no 
steroids commenced; 
C2 ipi+nivo delayed by 
4 weeks then continued 
Complete resolution at 7 
weeks 
PR (2.43 
months) 
Alive after 
31 months; 
PD at 16 
months 
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Figure 1: Proposed algorithms for investigation and management of neurological toxicity due to immune 
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